Cogent Biosciences, Inc. Common Stock (COGT) Financials
Key financial figures for Cogent Biosciences, Inc. Common Stock (Q3 2026).
Q3 2026 net loss widened to $111.4M as G&A tripled on launch preparation; $791.1M cash expected to fund operations into late 2028 ahead of the November 30 GIST PDUFA date. Net loss was $111.4M in Q3 2026 versus $80.9M in Q3 2025; loss from operations was $117.2M versus $83.4M (the release prints no per-share line; the 10-Q shows -$0.59 per share versus -$0.50). R&D expense was $75.1M versus $69.0M a year earlier, on the ongoing SUMMIT, PEAK and APEX trials and early-stage, preclinical and discovery programs; it includes $7.5M of non-cash stock compensation. G&A expense was $42.1M versus $14.4M, on commercial-readiness investment in personnel and infrastructure for the potential bezuclastinib launch; it includes $9.4M of non-cash stock compensation. On the outlook: The company believes its cash, cash equivalents and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements into late 2028, well past all three pending bezuclastinib PDUFA action dates (GIST November 30, 2026; NonAdvSM December 30, 2026; AdvSM June 29, 2027). INDs for CGT1815 and CGT1145 are planned in Q4 2026. Figures are for Q3 2026, as Cogent Biosciences reported them.
- Revenue
- $0
- Net Income
- -$111M
- EPS
- $-0.59
- Total Assets
- $832M
- Operating Cash Flow
- -$81M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $0 | -$111M | -$0.59 | -$81M | |
| Q2 FY2026 | $0 | -$96M | -$0.52 | -$78M | |
| Q1 FY2026 | $0 | -$97M | -$0.53 | -$87M | |
| Q4 FY2025 | $0 | -$102M | -$0.64 | -$80M | |
| Q3 FY2025 | $0 | -$81M | -$0.50 | -$64M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$329M | -$2.16 | -$266M | |
| FY2024 | $0 | -$256M | -$1.94 | -$208M | |
| FY2023 | $0 | -$192M | -$1.94 | -$156M |
Frequently asked questions
What was Cogent Biosciences's revenue last quarter?
Cogent Biosciences reported revenue of $0.00 for Q3 FY2026.
Is Cogent Biosciences profitable?
Not in its most recent reported period. Cogent Biosciences reported a net loss of $111.4 million for Q3 FY2026.
How much free cash flow did Cogent Biosciences generate?
Cogent Biosciences generated free cash flow of -$80.9 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Cogent Biosciences, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.